MG
SPRO icon

Michael Gelband’s Spero Therapeutics SPRO Stock Holding History

Michael Gelband’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,933
Closed -$153K – 2601
2021
Q2 		$153K Buy
+10,933
New +$153K ﹤0.01% 2055

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Michael Gelband's SPRO Position: Q3 2021 in Review

Michael Gelband sold out of Spero Therapeutics (SPRO) in Q3 2021, closing a stake of 10,933 shares — an estimated $153K sold.

Michael Gelband first reported a position in SPRO in Q2 2021 and held it in 1 quarter. The position peaked at $153K in Q2 2021. 87 funds tracked by Wall St. Rank hold SPRO as of Q3 2021.

  • Michael Gelband reported no remaining Spero Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 10,933 Spero Therapeutics shares in Q3 2021, an estimated $153K.
  • Michael Gelband first reported a position in Spero Therapeutics in Q2 2021 and held it in 1 quarter.
  • Michael Gelband's Spero Therapeutics position peaked at $153K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.